+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Biotech Advances for Disease Management

  • ID: 4451603
  • Report
  • January 2018
  • Region: Global
  • 15 pages
  • Frost & Sullivan
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

This edition of the Genetic Technology TOE depicts life sciences trends across disease management. Role of oncolytic viruses and gut microbiome in cancer immunotherapy is profiled in the TOE. Also profiled are a recent partnership among pharmaceutical companies, US FDA Breakthrough Therapy Designation received by a drug used for cytomegalovirus (CMV) treatment in transplant patients.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Note: Product cover images may vary from those shown
2 of 2

1. Recent Biotech Innovations for Disease Management

  • Leveraging Oncolytic Viruses for Enhancing Cancer Immunotherapy
  • Emerging Role of Gut Microbiome in Cancer Immunotherapy
  • Takeda Intends to Acquire TiGenix in a $632 Million Transaction
  • Maribavir Receives US FDA Breakthrough Therapy Designation

2. Clinical Trial Analysis and Industry Interactions

  • Summary of Clinical Studies for Cx601
  • Industry Interactions
Note: Product cover images may vary from those shown
3 of 2